<!DOCTYPE HTML>

<html>
	<head>
		<title>Pharmaceutical Industry in China</title>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
		<link rel="stylesheet" href="assets/css/main.css" />
	</head>
	<body class="is-preload">

		<!-- Wrapper -->
			<div id="wrapper">

				<!-- Main -->
					<div id="main">
						<div class="inner">

							<!-- Header -->
					

							<!-- Content -->
								<section>
									<header class="main">
										<h1 id="h1 top">Success Factor </h1>
									</header>

									<span class="image main"><img src="images/cover.gif" alt="" /></span>

					<hr class="major" />

									
									<h2 id="sf1">Policy & Regulation Support: Drug Administration Law</h2>
									<h3><u>Impact Across Value Chain</u></h3>
									<dl>
														<dt>Manufacturing</dt>
														<dd>
															<ul>
																<li>Establishing comprehensive quality control system: vaccine, blood products, narcotic drugs, psychotropic drugs, poisons for medical use are prohibited for outsourced manufacturing unless specified by National Drug Association</li>
																<li>Parties with Market Authorization (MA) are subject to specifying marketing regulations</li>
															</ul>
														</dd>
														<dt>Distribution</dt>
														<dd>
															<ul>
															<li>Establishing and reinforcing drug tracking system </li>
																<li>No online sales for specially administered drugs such as radiative drugs and poisonous drug-chemicals</li>
																<li>Safety, efficiency and cost-effectiveness as key pillars for the use of drugs for medical institutions</li>
																</ul>
														</dd>
														<dt>Supervision </dt>
														<dd>
															<ul>
																<li>Parties with MA are subject to post-marketing evaluations on safety, effectiveness and quality controllability of drugs and establishing annual reporting system</li>
																<li>Parties with conditional MA are subject to post-marketing risk management within pre-specified period</li>
															</ul>
														</dd>
													</dl>
													<h4><u>Renewed Incentives</u></h4>
															<ul>
																<li>Medical value as key orientation</li>
																<li>Incentivize innovative and child-use drugs</li>
																<li>Optimize TCM evaluation system</li>
																<li>Enhance approval process, expert connection</li>
																<li>Establish check-list system for inventory and shortage management</li>
																</ul>
																<h4><u>Stricter Punishment </u></h4>
																<span class="image fit"><img src="images/sf.png" alt="" /></span>												
									<h2 id="sf2">Distribution Channel </h2>
									<h3><u>Distribution format</u></h3>
									<dl>
														<dt>Direct distribution</dt>
														<dd>
															<ul>
																<li>Drugs are directly distributed from pharmaceutical manufacturers to patients</li>
																<li>Limited to over-the-counter drugs</li>
																<li>Via pharmaceutical company’s stores</li>
															</ul>
														</dd>
														<dt>Indirect distribution</dt>
														<dd>
															<ul>
															<li>Drugs go through wholesalers and retailers to reach patients</li>
																<li>Most common distribution format</li>
																</ul>
														</dd>
													</dl>
<h4><u>Distribution for different drugs</u></h4>
									<dl>
														<dt>Prescription drugs</dt>
														<dd>
															<ul>
																<li>Based on a physician’s prescription, the drug can be dispensed by a pharmacist to patients</li>
																<li>Only sales agencies that hold a "drug business license" can deploy and sell to patients</li>
														
															</ul>
														</dd>
														<dt>Over-the-counter A drugs</dt>
														<dd>
															<ul>
															<li>Only sales agencies that hold a "drug business license" can deploy and sell to patients</li>
																</ul>
														</dd>
														<dt>Over-the-counter B drugs</dt>
														<dd>
															<ul>
															<li>Retail pharmacy and approved general stores can deploy and sell to patients</li>
																</ul>
														</dd>
													</dl>

													<h4><u>Improvement factors</u></h4>
									<dl>
														<dt>Development of pharmaceutical companies</dt>
														<dd>
															<ul>
																<li>Choosing a good market selling point is the key to success for pharmaceutical companies. Therefore, they would conduct in-depth researches on the current pharmaceutical distribution channels</li>
																<li>By establishing an agile and practical distribution channels, the companies will be able to supply and sale drugs to patients on time and fulfill their healthcare needs</li>
												
															</ul>
														</dd>
														<dt>Growing pharmaceutical demands</dt>
														<dd>
															<ul>
															<li>Increasing average wages</li>
																
																<li>Aging population</li>
																<li>Enhancing awareness of healthcare</li>
																<li>Increasing demands of medical quality</li>
																<li>Improving medical insurance system</li>
																</ul>
														</dd>
														<dt>Improvement on consumers</dt>
														<dd>
															<ul>
															<li>To resolve issues correlated with retail drug sales, modern technology such as telemarketing, online sales, mail order can build multiple distribution channels</li>
																<li>By educating the general public to consume drugs more reasonably and promoting related healthcare knowledge, retail pharmacies will be the major distribution channel for generic drugs</li>
																</ul>
														</dd>
														<dt>Improvement of retail sales</dt>
														<dd>
															<ul>
															<li>Drugs go through wholesalers and retailers to reach patients</li>
																<li>Standard models for pharmacy chains can establish unified service specifications, unified price, unified management, unified accounting, and unified distribution and purchase</li>
																</ul>
														</dd>
														<dt>Cancellation of local protection</dt>
														<dd>
															<ul>
															<li>China cancels policies that protects local pharmaceutical markets. This solves the problems of inter-provincial chain operation of pharmaceutical industry and the entry of pharmaceutical companies into rural markets. Also, it creates a more eased environment for the development of pharmaceutical companies</li>
																</ul>
														</dd>
													</dl>
				

								</section>
								<section>
									<header class="major">
										<h2>Analysis</h2>
									</header>
									<div class="posts">
										<article>
											<a href="io.html" class="image"><img src="images/cover.png" alt="" /></a>
											<h3>Industry Overview</h3>
											<p>Customer Segmentation | Overview of China Healthcare Industry | Overview of China Drug Industry</p>
											<ul class="actions">
												<li><a href="io.html" class="button primary">More</a></li>
											</ul>
										</article>
										<article>
											<a href="icv.html" class="image"><img src="images/ivc_c.jpg" alt="" /></a>
											<h3>Industry Value Chain</h3>
											<p>The Life of a Drug | 
												Demystifying R&D + Drug Registration | 
												Supply Chain and Major Players (Competitive Landscape) </p>
											<ul class="actions">
												<li><a href="ivc.html" class=" button primary">More</a></li>
											</ul>
										</article>
										<article>
											<a href="sf.html" class="image"><img src="images/sf_c.jpg" alt="" /></a>
											<h3>Success Factor</h3>
											<p>Policy & Regulation Support | 
												Distribution Channel</p>
											<ul class="actions">
												<li><a href="sf.html" class="primary button">More</a></li>
											</ul>
										</article>
										
										<article>
											<a href="cs.html" class="image"><img src="images/cs_c.jpg" alt="" /></a>
											<h3>Case Study</h3>
											<p>Company 1 - Sino | Company 2 - Henrui</p>
											<ul class="actions">
												<li><a href="cs.html" class="primary button">More</a></li>
											</ul>
										</article>
										<article>
											<a href="ft.html" class="image"><img src="images/ft_c.jpg" alt="" /></a>
											<h3>Future Trend</h3>
											<p>Regulatory and Policy: Centralized Procurement | National Reimbursement Drug List (NRDL)</p>
											<ul class="actions">
												<li><a href="ft.html" class="primary button">More</a></li>
											</ul>
										</article>
										<article>
											<a href="ij.html" class="image"><img src="images/ij_c.jpg" alt="" /></a>
											<h3>Glossary</h3>
											<p>Industrial Jardon | Interesting Video</p>
											
											<ul class="actions">
												<li><a href="ij.html" class=" primary button">More</a></li>
											</ul>
										</article>
									</div>
								</section>

						</div>
					</div>

				<!-- Sidebar -->
					<div id="sidebar">
						<div class="inner">

							<!-- Menu -->
								<nav id="menu">
									<header class="major">
										<h2>Menu</h2>
									</header>
									<ul>
										<li><a href="index.html#h1">Homepage</a></li>
										<li>
											<span class="opener">Industry Overview</span>
											<ul>
												<li><a href="io.html#io1">Custom Segmentation</a></li>
												<li><a href="io.html#io3">Overview of China Healthcare Industry</a></li>
												<li><a href="io.html#io4">Overview of China Drug Industry</a></li>
											</ul>
										</li>
										<li>
											<span class="opener">Industry Value Chain</span>
											<ul>
												<li><a href="ivc.html#ivc1">The Life of a Drug</a></li>
												<li><a href="ivc.html#ivc2">Demystifying R&D + Drug Registration</a></li>
												<li><a href="ivc.html#ivc3">Supply Chain and Major Players </a></li>
											</ul>
										</li>
										<li>
											<span class="opener">Success Factor</span>
											<ul>
												
												<li><a href="sf.html#sf1">Policy & Regulation Support</a></li>
												<li><a href="sf.html#sf2">Distribution Channel</a></li>
											</ul>
										</li>
										

										<li>
											<span class="opener">Future Trend</span>
											<ul>
												<li><a href="ft.html#ft1">Regulatory and Policy: <br/>Centralized Procurement </a></li>
												<li><a href="ft.html#ft2">National Reimbursement Drug List (NRDL)</a></li>
											</ul>
										</li>
										
										<li>
											<span class="opener">Case Study </span>
											<ul>
												<li><a href="cs.html#c1">Company 1 - Sino</a></li>
												<li><a href="cs.html#c2">Company 2 - Henrui</a></li>
											</ul>
										</li>
										<li>
											<span class="opener">Glossary </span>
											<ul>
												<li><a href="ij.html#ij1">Industrial Jardon</a></li>
												<li><a href="ij.html#ij2">Interesting Video</a></li>
											</ul>
										</li>
										
									</ul>
								</nav>

							<!-- Section -->
							
								<section>
									<header class="major">
										<h2>Latest News</h2>
									</header>
									<div class="mini-posts">
										<article>
											<a target="_blank" href="https://www.economist.com/business/2019/09/28/chinas-pharmaceuticals-industry-is-growing-up" class="image"><img src="images/n1.jpg" alt="" /></a>
											<p>The Economist - China’s pharmaceuticals industry is growing up </li></p>
										</article>
										<article>
											<a target="_blank" href="https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/chinese-growth-shots-some-years-away-for-pharma-companies/articleshow/71513734.cms" class="image"><img src="images/n2.jpg" alt="" /></a>
											<p>The Economic Times - Chinese growth shot’s some years away for pharma companies </p>
										</article>
										<article>
											<a target="_blank" href="https://www.chinadaily.com.cn/a/201908/14/WS5d536f5ea310cf3e35565a93.html" class="image"><img src="images/n3.jpg" alt="" /></a>
											<p>China Daliy - Pharma companies undergoing critical transformation</p>
										</article>
										<article>
											<a target="_blank" href="https://www.pharmaceutical-technology.com/comment/china-pharmaceutical-industry-2019/" class="image"><img src="images/n4.jpg" alt="" /></a>
											<p>Pharmaceutical Technology - Characterising Eastern China’s pharmaceutical manufacturing market: Shandong and Jiangsu</li></p>
										</article>
										<article>
											<a target="_blank" href="https://www.expresspharma.in/cover-story/is-china-the-next-land-of-opportunity/" class="image"><img src="images/n5.jpg" alt="" /></a>
											<p>Express Pharma - Is China the next land of opportunity? </p>
										</article>
										
									</div>
									
								</section>

							<!-- Section -->
							
								<section>
									<header class="major">
										<h2>Get in touch</h2>
									</header>
							
									<ul class="contact">
										<li class="icon solid fa-envelope"><a href="mailto:haa300.2019@gmail.com">haa300.2019@gmail.com</a></li>
									
									</ul>
									
										<h2 class="major"><a href="#top">Back to Top</a></h2>
								

							<!-- Footer -->
								<footer id="footer">
									<p class="copyright">&copy; Untitled. All rights reserved. <br/> Edited by GROUP E @ Fall 2020 - GBUS3030
										<br/> Nov 28, 2019</p>
								</footer>
								
						</div>
					</div>

			</div>

		<!-- Scripts -->
			<script src="assets/js/jquery.min.js"></script>
			<script src="assets/js/browser.min.js"></script>
			<script src="assets/js/breakpoints.min.js"></script>
			<script src="assets/js/util.js"></script>
			<script src="assets/js/main.js"></script>

	</body>
</html>